Cel-Sci has a 3000 Percent Increase Potential
August 07, 2009
– Comments (38) |
RELATED TICKERS: CVM
In the next three years Cel-Sci could light up the Biotech world by releasing Phase III results on a new product called Multikine®.
Multikine® is CEL-SCI’s late stage cancer product, which is an immunotherapeutic agent for first-line standard of care treatment in head and neck cancer patients. The drugs approach is different in the way it fights against cancer, by directly affecting both the tumor cells and by activating an anti-tumor immune response by the body.
This multipronged approach has produced fabulous Phase II results. Multikine achieved a 33% improvement in median overall survival at a median of 3.5 years post surgery with no adverse events. Along with these impressive safety and efficacy results, Multikine showed a 50% reduction in tumor cells, 12% complete response, 8% increase in the Local Regional Control.
Folks I’m not usually this gitty, but the Phase II results are just not seen like this! I also like the risk factors ahead. Multikine will only need to demonstrate a 10% improvement in overall survival for the Phase III trials to be successful. We have a good 20% to play with from the Phase II results.
So why is Cel-Sci’s stock at $0.48 for today’s close and its market cap sitting on a measly 62M? Its because Wall Street is wondering why a US partner has not yet been identified if you ask me. So why am I not worried about this pending risk? Because TEVA has already signed for the Israeli market and they are about the most conservative company known to man on the branded side. They see the clinical risk being very low and the potential for a best in class product being high – just like I do!
Before I get too long winded let me tell you a few other reasons why I like the stock; Cel-Sci has enough cash until next March (unusual for Biotech’s in this credit climate), has only 130M shares outstanding, and is finishing up on its manufacturing facility where it plans to make its Phase III clinical trial material.
As with the other Biotech’s I’ve recommended I’m in for a handsome sum!
I’ll keep you posted
Becon800